| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Ahrens Brenton Karl is a Director at Iterum Therapeutics plc. Recent SEC Form 4 filings include 1 buy and 9 sells.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 20, 2022 | ITRM Iterum Therapeutics Plc | Director | Sell | 37,246 | $1.82 | $67,930.20 | -55.8% | -44.2% | -59.4% | |
| Sep 15, 2022 | ITRM Iterum Therapeutics Plc | Director | Sell | 45,000 | $2.09 | $93,846.00 | -22.3% | -43.0% | -61.0% | |
| Sep 12, 2022 | ITRM Iterum Therapeutics Plc | Director | Sell | 33,298 | $2.31 | $76,802.52 | -10.2% | -49.8% | -65.3% | |
| May 30, 2018 | ITRM Iterum Therapeutics Plc | Director | Buy | 506,656 | $13.00 | $6,586,528.00 | +41.3% | - | - |